Old Web
English
Sign In
Acemap
>
Paper
>
OUTCOMES FOR MYELOFIBROSIS PATIENTS WHO SWITCHED FROM FEDRATINIB TO RUXOLITINIB THERAPY
OUTCOMES FOR MYELOFIBROSIS PATIENTS WHO SWITCHED FROM FEDRATINIB TO RUXOLITINIB THERAPY
2014
N.C García
Tim C.P. Somervaille
Clodagh Keohane
J. Chadwick
Adam J. Mead
S. Rhodes
Mark W. Drummond
Joanne Ewing
Deepti Radia
Christine J. Harrison
Keywords:
Immunology
Fedratinib
Oncology
Ruxolitinib
Medicine
Myelofibrosis
Internal medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]